コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 drugs that promote hypokalemia; or using an alternative therapy.
2 urce utilization for HF, and is an effective alternative therapy.
3 ow-stage patients that could benefit from an alternative therapy.
4 mptothecin (CPT) has emerged as an effective alternative therapy.
5 symptoms and who often do not have adequate alternative therapy.
6 ely to have superior responses to a specific alternative therapy.
7 r resistance but was usually treatable using alternative therapy.
8 n with adverse reactions and to prescribe an alternative therapy.
9 d residual disease classes to be assigned an alternative therapy.
10 ship pharmacist provided recommendations for alternative therapy.
11 isease after initial therapy crossed over to alternative therapy.
12 2C19 genetic testing and can be treated with alternative therapy.
13 tified and offered a detailed evaluation and alternative therapy.
14 ulation and lacks accurate information about alternative therapy.
15 ecommendation for chronic transfusions as an alternative therapy.
16 spoke device for this patient with no viable alternative therapy.
17 esponse to proton-pump inhibitors often seek alternative therapy.
18 sistant strains, creating an urgent need for alternative therapy.
19 The adverse effects of 5ARIs encourage alternative therapy.
20 hibitor therapy compared to disease-specific alternative therapy.
21 st that these patients may be candidates for alternative therapies.
22 O, there has been a strong effort to develop alternative therapies.
23 idated intermediate end points and effective alternative therapies.
24 tal glomerulosclerosis, its pathogenesis and alternative therapies.
25 peppermint oil are among the most promising alternative therapies.
26 se at 3 to 6 months should be considered for alternative therapies.
27 ations against antibiotic use and to suggest alternative therapies.
28 ytogenetic features should be considered for alternative therapies.
29 care providers about these complementary and alternative therapies.
30 to use these and many other complementary or alternative therapies.
31 new antibiotic treatments and to research on alternative therapies.
32 ication, nonstimulant medication, as well as alternative therapies.
33 djuvant treatment and nonresponders who need alternative therapies.
34 or ablation should be considered as possible alternative therapies.
35 tive" phenotype that requires exploration of alternative therapies.
36 or these problems also use complementary and alternative therapies.
37 zation, and iron overload suggest a need for alternative therapies.
38 population warrants the future use of novel alternative therapies.
39 is a powerful decision aid in choosing among alternative therapies.
40 ies, over-the-counter hormonal products, and alternative therapies.
41 those surveyed reported relying primarily on alternative therapies.
42 ting new drugs are difficult to compare with alternative therapies.
43 t common reasons for using complementary and alternative therapies.
44 proactively discuss the use or avoidance of alternative therapies.
45 e early identification of children requiring alternative therapies.
46 ythms are illuminating new possibilities for alternative therapies.
47 ance and toxicity, highlighting the need for alternative therapies.
48 y and tolerability, emphasizing the need for alternative therapies.
49 ons and other mechanisms, which necessitates alternative therapies.
50 with higher surgical risk and higher-dose or alternative therapies.
51 prove one's baseline physical health through alternative therapies.
52 mour types, but not in patients treated with alternative therapies.
53 nic acid (HA) and a small number of unproven alternative therapies.
54 erapy is moderate, highlighting the need for alternative therapies.
55 GF agents, personalized treatment plans, and alternative therapies.
56 d at infection prevention and evidence-based alternative therapies.
57 of younger and more active patients mandates alternative therapies.
58 t failure and lay a conceptual framework for alternative therapies.
59 iron in heart failure, safety concerns, and alternative therapies.
60 g refills, taking less medication, and using alternative therapies.
61 ital infections, it is important to research alternative therapies.
62 nform their patients who may be in search of alternative therapies.
63 These considerations emphasize the need for alternative therapies.
64 mmunoglobulin products has led to search for alternative therapies.
65 tients are commonly targeted by providers of alternative therapies.
66 bacterium tuberculosis stresses the need for alternative therapies.
67 imatinib exposure, underscores the need for alternative therapies.
68 c-resistant pathogens highlight the need for alternative therapies.
69 k patients who require more intensive and/or alternative therapies.
70 t 25 y, underscoring the urgent need for new alternative therapies.
71 een an inadequate response or intolerance to alternative therapies.
72 rates of relapse, supporting the need to use alternative therapies.
73 ms of hazard ratios comparing sorafenib with alternative therapies according to hepatitis C virus (HC
74 2 [95% CI, 23.0-23.4] percentage points) and alternative therapies (adjusted difference, 4.8 [95% CI,
75 ify and characterize the range of unorthodox alternative therapies advertised to patients with a diag
76 acteroidal QC inhibitors, paving the way for alternative therapies against periodontitis and associat
78 y, the use of phages has been proposed as an alternative therapy against multidrug-resistant bacteria
81 er, who could then consult the prescriber on alternative therapies and implement more intensive monit
82 or designing more systematic explorations of alternative therapies and improving predictive accuracy.
83 astration resistance urges the generation of alternative therapies and represents an important health
84 utation is highlighted by the limitations of alternative therapies and the potential for rapid, globa
87 iteria, the clinical use of terlipressin and alternative therapies, and identify areas of future rese
91 in cat, and they highlight a possibility for alternative therapies applied at ages thought to be reca
100 nergics remain the first-line treatment, but alternative therapies are undergoing clinical trials.
103 by a set of standard chemotherapy drugs, and alternative therapies are used only when a patient has d
104 es may determine whether close monitoring or alternative therapies are warranted for patients with mi
105 istance exercise training (RET), a potential alternative therapy, are well established, but mental he
106 study that compares FCR treatment with newer alternative therapies as part of a randomised clinical t
107 vascular access challenges with no realistic alternative therapy available, and those who have been a
109 Here, we describe development of a low-cost alternative therapy based on intratumoral ethanol inject
110 ng 5 pancreatic cancer treatment modalities (alternative therapy, chemotherapy, clinical trials, radi
111 hageal variceal hemorrhage compared with all alternative therapies combined (relative risk [RR], 0.63
112 heir reasons for nondisclosure of use of 726 alternative therapies, common reasons for nondisclosure
114 acrolimus is the best primary treatment, but alternative therapies could be instituted in severe case
116 g-term outcomes, comparing this treatment to alternative therapies, developing listing and allocation
119 antithrombotic for type 2 diabetes and that alternative therapies (e.g. combinations with clopidogre
120 patients, there has been renewed interest in alternative therapies, especially the ketogenic diet.
122 of placebo-controlled trials when effective alternative therapy exists, regardless of the expected e
124 nical assessment and treatment of BPD, e.g., alternative therapies for BPD such as gradual exposure t
126 eting of the MYC pathway remains limited and alternative therapies for G3 MB are urgently needed.
127 There is a continuing need for innovative, alternative therapies for hepatocellular carcinoma (HCC)
128 transplantation has prompted the search for alternative therapies for intractable liver diseases.
131 ptimal medical therapy (OMT) are comparable, alternative therapies for many patients with stable angi
132 erapeutic approaches and nonmyelosuppressive alternative therapies for myelodysplasia have been studi
133 losporin allergies; there are no recommended alternative therapies for N gonorrhoeae infection of the
135 nutritional supplements have emerged as safe alternative therapies for osteoarthritis (OA), a chronic
136 e collateral development and thereby provide alternative therapies for patients with vascular disease
138 n reference to cost and efficacy analyses of alternative therapies for sickle cell disease, such as a
141 he past few years, progress has been made in alternative therapies for supporting children and adults
142 e treatment roles and toxicities of WBRT and alternative therapies for the management of brain metast
143 formation on the use of 24 complementary and alternative therapies for the treatment of specific chro
148 metformin for those predicted to respond and alternative therapies for those predicted to be nonrespo
150 he past few years, progress has been made in alternative therapies for ventilating both children and
151 r 8 weeks, a 2-week washout period, then the alternative therapy for 8 weeks) was conducted among 20
153 the introduction of parasites as a potential alternative therapy for asthma and other immunological d
154 ation of T-cell costimulation may also be an alternative therapy for children with JIA who are resita
161 lements containing botanical ingredients, as alternative therapy for infectious diseases, has been in
162 ssal nerve stimulation (HGNS) is a potential alternative therapy for obstructive sleep apnea (OSA), b
164 was shown by this study to be an acceptable alternative therapy for patients with active WG, includi
167 ure by soy isoflavones have implications for alternative therapy for postmenopausal women and patient
169 ota transplantation (FMT), a safe, effective alternative therapy for recurrent Clostridium difficile
171 est imatinib is well tolerated and may be an alternative therapy for some patients with AIDS-KS.
173 cterial viruses, are now seen as a potential alternative therapy for these infections, but most of th
176 emic cell survival, KPT-330 may represent an alternative therapy for TKI-refractory Ph(+) leukemias.
177 l magnetic stimulation (rTMS) is a promising alternative therapy for treatment-resistant depression,
178 otential K. pneumoniae vaccine candidates or alternative therapies have been launched in recent years
180 oral treatments, probiotics, antibiotics and alternative therapies - have developing roles in the tre
181 the widespread adoption of complementary and alternative therapies; however, the prevalence of their
182 i-EGFR responses or to be used to develop an alternative therapy if EGFR was not present.In-vivo expe
184 ited number of drugs are used as standard or alternative therapies in autoimmune hepatitis (AIH).
185 ed to be as effective or more effective than alternative therapies in improving several common RA dis
186 ice to consider overall clinical context and alternative therapies in the decision to perform platele
187 rials into the efficacy of complementary and alternative therapies in the treatment of depression.
188 ttention has also been focused on the use of alternative therapies in the treatment of HLA-B27-associ
190 d cisplatin therapy, suggesting the need for alternative therapies in this cohort of high-risk patien
191 llele carriers, MAE risk appeared lower with alternative therapy in both the group with scores <10 (w
193 score, while clopidogrel is as effective as alternative therapy in non-LOF patients with scores <10.
194 GODZ shRNA, should be considered a potential alternative therapy in not only HSV-1 but also other con
195 e, and there is no class 1 evidence to guide alternative therapy in patients with breakthrough diseas
196 t ventricular assist device is an acceptable alternative therapy in selected patients who are not can
197 contemporary therapy, should be assigned to alternative therapy in the context of a prospective clin
199 tions, pharmacotherapy, and complementary or alternative therapy) in adults, including pregnant women
200 l treatments for T2D, highlighting potential alternative therapies including fecal microbiota transpl
201 ith both nonstimulant medications as well as alternative therapies, including diet, iron supplementat
204 ral therapies is reviewed and information on alternative therapies, including nutriceuticals and acup
205 mes are comparable to prospective reports of alternative therapies, including stereotactic body radia
206 of amphotericin B plus flucytosine, and the alternative therapy is 2 weeks of fluconazole plus flucy
207 bacterial infections in countries where this alternative therapy is approved, many scientists and com
208 ng of fulminant hepatic failure, for whom no alternative therapy is available, may be candidates for
210 atients with distal colitis; and (5) role of alternative therapies like probiotics, curcumin, and fec
214 of children with atopic dermatitis had used alternative therapies, most commonly due to fears of top
216 iated FGF2 gene delivery has potential as an alternative therapy of Alzheimer's disease and possibly
217 ts of dupilumab treatment in comparison with alternative therapies on the frequency of MBC2s and the
218 d increased scar size, suggesting that these alternative therapies, on average, may not be superior t
219 der, an infectious disease etiology provides alternative therapy opportunities for this devastating d
220 mmunopharmacotherapy is being explored as an alternative therapy option and is based upon antibody-op
222 ntification of patients who may benefit from alternative therapy or who may be spared possible overtr
226 up (GOG) provides strong evidence that a new alternative therapy--paclitaxel (Taxol; Bristol-Myers Sq
227 in the proportion of the population seeking alternative therapies, rather than increased visits per
228 afety profile is acceptable compared with an alternative therapy regarding the time to a clinical eve
231 em cells (BM-MSCs) has been considered as an alternative therapy, replacing liver transplantation in
232 nfarction and death and to relieve symptoms, alternative therapy, revascularization to improve surviv
233 nts except fluoxetine in this age group, and alternative therapies should be sought in the first inst
235 atient receipt of 1 of 10 novel therapies vs alternative therapies specific to the patient's cancer f
238 tion, highlighting the potential need to use alternative therapies such as leukotriene receptor antag
239 ment to be modified to include additional or alternative therapy such as bone marrow transplantation.
240 ing several limitations, we have explored an alternative therapy such as nano-clays; nano-sized natur
241 or type and conditioning regimens, or indeed alternative therapies (such as gene therapy) to specific
243 o received an immediate, non-cross resistant alternative therapy (switch maintenance) after first-lin
244 Consequently, there exists a need to develop alternative therapies that more effectively target the c
248 loid B-cell ALL (B-ALL), for which effective alternative therapies to current intensive chemotherapy
252 from another country to save money, and used alternative therapies to save money) and race and ethnic
254 ication of patients at high risk who require alternative therapies to the current standard of care is
255 ice to consider overall clinical context and alternative therapies to transfusion when making transfu
256 resents data on the use of complementary and alternative therapies to treat anxiety and depression in
257 e could be a potential target for developing alternative therapies to treat E. faecalis infections.
258 depression reported using complementary and alternative therapies to treat these conditions during t
260 t or reduced toxicity are actively sought as alternative therapy to a gluten-free diet (GFD) for pati
263 ommends mandibular advancement devices as an alternative therapy to continuous positive airway pressu
265 affinity for DNA topoisomerases may offer an alternative therapy to overcome breakthrough infections
266 rthermore, GCK inhibitors might represent an alternative therapy to overcome immunomodulatory drug re
267 Silver diamine fluoride (SDF) may provide an alternative therapy to prevent and control caries if sho
268 ntists around the globe are searching for an alternative therapy to provide better treatment to the s
269 ence supporting the use of ranibizumab as an alternative therapy to PRP for PDR, at least through 2 y
270 traindicated for some patients, we sought an alternative therapy to reduce tumor-associated bone dest
272 The achievement of these goals makes TMR an alternative therapy to what was formerly the only therap
274 <10 (n = 3,200), MAE was not different with alternative therapy vs clopidogrel (weighted HR: 0.89; 9
276 1997 out-of-pocket expenditures relating to alternative therapies were conservatively estimated at $
277 e rates between the 2 survey years; 39.8% of alternative therapies were disclosed to physicians in 19
279 l clinical context, patient preferences, and alternative therapies when making transfusion decisions
281 refully and highly selected patients with no alternative therapy will provide the foundation upon whi
282 valve with cerebral embolic protection is an alternative therapy with promising mid-term outcomes whe